GLPwatch
Trials (2036)
Page 18 of 34.
- A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus
- Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
- Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia
- Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus
- A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants
- GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
- ECHO for Diabetes and Multiple Chronic Conditions Study
- Role Of Metabolic Adaptation In Weight Regain
- Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients
- MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
- Liraglutide Use in Prader-Willi Syndrome
- Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes
- Oat Flakes β-glucan on Glycemic Variability, Pancreatic Reserve, and Dyslipidemia Among Adolescents With Type 1 Diabetes
- GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis
- A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice
- Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
- A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects
- Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction
- An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
- A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
- Protein Supplementation Intervention on Body Weight
- Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
- Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance
- Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes
- The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis
- Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus
- GLP_1 RA Ultrasound Study
- Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin
- Body Surface Gastric Mapping in Patients on Semaglutide
- Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke
- Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
- Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.
- A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)
- Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
- Study That Tests AD109 in Patients Taking GLP-1 Drugs
- A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
- A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World
- Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
- A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body
- Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery
- Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients
- A Study of a Novel Precision Medicine Approach For Obesity
- A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
- A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
- Comparison of Three Liraglutide Formulations in Healthy Volunteers
- A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes
- Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
- Oral Semaglutide in Patients With Alzheimer's Disease
- 24-h Energy Expenditure and Anti-obesity Medication
- Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
- Ultrasound Assessment of the Carotid Intimal Medial Thickness in Obese Subjects; Weight Loss
- Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
- Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
- SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease
- Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes
- Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent
- Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy